Long-term immunogenicity of a single-dose live recombinant chimeric Japanese encephalitis vaccine in adults
Journal of Travel Medicine · 2025
DOI: 10.1093/jtm/taaf006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Travel Medicine, 2025. Verfasst von Deborah J Mills und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dr Deb The Travel Doctor, Travel Medicine Alliance, Brisbane, Australia. Hauptthemen laut MEDLINE: Japanese Encephalitis Vaccines, Encephalitis, Japanese, Immunogenicity, Vaccine. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Infectious Disease Research Centre, NHMRC Investigator, University of Queensland's Amplify Initiative.
Abstract (Originalsprache)
Background
Japanese encephalitis virus is a leading cause of viral encephalitis in Asia, with high case-fatality rate and morbidity. Although the live recombinant Japanese encephalitis chimeric vaccine (Imojev®) offers strong initial immunity, data on long-term efficacy beyond 5 years remain limited.
Methods
We conducted a cross-sectional study on adults vaccinated with Imojev® at a specialist travel clinic in Brisbane, Australia. Participants were stratified based on the time since vaccination: 2–5 years and >5 years. Neutralizing antibody titres were measured using the plaque reduction neutralization test (PRNT50), with titres ≥10 indicating seropositivity.
Results
Of the 103 participants, 47 were vaccinated 2–5 years prior and 56 were vaccinated ≥5 years prior to enrolment. All participants vaccinated within 5 years remain seropositive, whilst 52 of 56 (92.9%) vaccinated ≥5 years ago were seropositive. Four participants (7.1%) were seronegative post-vaccination, with time since vaccination ranging from 5 to 9 years. These seronegative individuals were vaccinated a median of 9.2 years ago, compared to 5.1 years for seropositive participants (P-value = 0.037). Aside from time since vaccination, no other factors (e.g. age, sex) were associated with seronegativity.
Conclusions
Imojev® provides durable immunity, with seropositivity exceeding 90% up to 10 years post-vaccination. However, waning immunity in a small proportion of individuals suggests that booster doses may be beneficial for high-risk travellers vaccinated over 5 years ago.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dr Deb The Travel Doctor, Travel Medicine Alliance, Brisbane, Australia.
- UQ Centre for Clinical Research, Faculty of Health, Medicine, and Behavioural Sciences, The University of Queensland, Herston, Australia.
- Mosquito Control Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Förderung
- Australian Infectious Disease Research Centre
- NHMRC Investigator
- University of Queensland's Amplify Initiative
- University of Queensland’s Amplify Initiative
Zitieren
APA
Mills, D. J., Gyawali, N., Nammunige, N. A., Mills, C., Devine, G. J., Lau, C. L., & Furuya-Kanamori, L. (2025). Long-term immunogenicity of a single-dose live recombinant chimeric Japanese encephalitis vaccine in adults. Journal of Travel Medicine. https://doi.org/10.1093/jtm/taaf006
Vancouver
Mills DJ, Gyawali N, Nammunige NA, Mills C, Devine GJ, Lau CL, et al. Long-term immunogenicity of a single-dose live recombinant chimeric Japanese encephalitis vaccine in adults. Journal of Travel Medicine. 2025. doi:10.1093/jtm/taaf006
BibTeX
@article{Mills2025,
author = {Mills, Deborah J and Gyawali, Narayan and Nammunige, Nirupama A and Mills, Christine and Devine, Gregor J and Lau, Colleen L and Furuya-Kanamori, Luis},
title = {Long-term immunogenicity of a single-dose live recombinant chimeric Japanese encephalitis vaccine in adults},
journal = {Journal of Travel Medicine},
year = {2025},
doi = {10.1093/jtm/taaf006}
}
EUVIMED